LPAR1 and pulmonary fibrosis: In particular, targeting LPA1 has become a promising strategy for drug development due to clinical trials for pulmonary fibrosis (ClinicalTrials.gov ID: NCT01766817) and psoriasis (ClinicalTrials.gov ID: NCT02763969).